Tate & Lyle plc (TATE.L)
London, GB
Established in 1903 and headquartered in London, United Kingdom, Tate & Lyle PLC is a global provider of specialized ingredients and solutions. The company caters to the food, beverage, and other industrial sectors across the United States, the United Kingdom, other European nations, and numerous international markets. Its operations are organized into three principal segments: Food & Beverage Solutions, Sucralose, and Primary Products. Tate & Lyle's diverse product portfolio encompasses texturants, health and wellness components, and stabilizers. They also supply nutritive sweeteners, such as high-fructose corn syrup and dextrose. Beyond food-related offerings, the company manufactures industrial starches for applications like paper, packaging, and adhesives, alongside acidulants like citric acid. Furthermore, they deal in various commodities, including corn gluten feed and meal for animal nutrition, corn oil, and ethanol. The company's activities extend to treasury, insurance, and vital research and development services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.10% | -4.51% | +45.29% | +25.43% | +42.04% | +35.67% | -8.21% | -35.18% | -37.50% | -16.74% | -47.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | +1 |
| Buy | 7 | 0 |
| Hold | 5 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Packaged Foods: +4.4%+15.6% ★ Q1'26: +24.3% (vs Q1'24)
-
EPS growth Packaged Foods: +14.6%+83.3% ★ Q1'26: -56.4% (vs Q1'24)
-
FCF margin FCF growth · Packaged Foods: +15.9%+5.1% ★ Q1'26: +5.3% (vs Q1'24)
-
EBIT margin Packaged Foods: +7.9%+9.0% ★ Q1'26: +8.4% (vs Q1'24)
-
ROIC Packaged Foods: +7.0%+5.3% Q1'26: +9.3% (vs Q1'24)
-
Share dilution Packaged Foods: +0.0%+7.7% Q1'26: +10.9% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Packaged Foods: 0.19×3.68× Q1'26: 1.93× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 11 Rev. Ana. 9 EPS Ana. |
Mar 2027 6 Rev. Ana. 3 EPS Ana. |
Mar 2028 11 Rev. Ana. 9 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
Mar 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.72B
est: 2.68B (+1.3%)
|
3.09B
est: 3.05B (+1.4%)
|
3.26B
est: 3.33B (-2.2%)
|
2.75B
est: 3.36B (-17.9%)
|
2.34B
est: 2.65B (-11.5%)
|
2.36B
est: 2.37B (-0.8%)
|
2.75B
est: 2.69B (+2.4%)
|
2.71B
est: 2.75B (-1.6%)
|
2.76B
est: 2.76B (-0.3%)
|
2.88B
est: 2.84B (+1.4%)
|
1.21B
est: 2.81B (-56.8%)
|
1.38B
est: 1.37B (+0.4%)
|
1.75B
est: 1.77B (-0.9%)
|
1.65B
est: 1.69B (-2.4%)
|
1.74B
est: 1.76B (-1.2%)
|
2.01B
1.96B – 2.04B
+14.4% YoY
|
2.03B
2.01B – 2.04B
+0.8% YoY
|
2.09B
2.02B – 2.18B
+3.3% YoY
|
2.16B
2.14B – 2.18B
+3.2% YoY
|
2.26B
2.22B – 2.32B
+4.8% YoY
|
| EBITDA |
404.00M
est: -43.35M (+1,032.0%)
|
586.00M
est: 303.05M (+93.4%)
|
449.00M
est: 496.64M (-9.6%)
|
417.00M
est: 401.16M (+3.9%)
|
166.00M
est: 319.61M (-48.1%)
|
270.00M
est: 146.57M (+84.2%)
|
415.00M
est: 329.04M (+26.1%)
|
436.00M
est: 400.50M (+8.9%)
|
423.00M
est: 440.37M (-3.9%)
|
501.00M
est: 406.72M (+23.2%)
|
292.00M
est: 462.72M (-36.9%)
|
168.00M
est: 476.16M (-64.7%)
|
279.00M
est: 487.54M (-42.8%)
|
345.00M
est: 489.36M (-29.5%)
|
254.00M
est: 290.96M (-12.7%)
|
327.01M
318.53M – 332.24M
+12.4% YoY
|
329.50M
327.27M – 331.46M
+0.8% YoY
|
340.30M
328.07M – 354.71M
+3.3% YoY
|
351.15M
348.57M – 353.72M
+3.2% YoY
|
368.03M
360.07M – 377.04M
+4.8% YoY
|
| EBIT |
295.00M
est: 5.88M (+4,919.1%)
|
483.00M
est: 343.92M (+40.4%)
|
335.00M
est: 445.87M (-24.9%)
|
314.00M
est: 332.82M (-5.7%)
|
57.00M
est: 253.97M (-77.6%)
|
155.00M
est: 30.23M (+412.7%)
|
266.00M
est: 144.60M (+84.0%)
|
319.00M
est: 238.66M (+33.7%)
|
271.00M
est: 287.63M (-5.8%)
|
329.00M
est: 242.39M (+35.7%)
|
117.00M
est: 292.66M (-60.0%)
|
68.00M
est: 301.16M (-77.4%)
|
184.00M
est: 308.36M (-40.3%)
|
251.00M
est: 309.51M (-18.9%)
|
126.00M
est: 167.98M (-25.0%)
|
188.80M
183.90M – 191.81M
+12.4% YoY
|
190.24M
188.95M – 191.37M
+0.8% YoY
|
196.47M
189.41M – 204.79M
+3.3% YoY
|
202.73M
201.24M – 204.22M
+3.2% YoY
|
212.48M
207.88M – 217.68M
+4.8% YoY
|
| Net Income |
163.00M
est: 11.02M (+1,379.1%)
|
305.00M
est: 185.01M (+64.9%)
|
272.00M
est: 336.61M (-19.2%)
|
273.00M
est: 274.37M (-0.5%)
|
30.00M
est: 213.33M (-85.9%)
|
163.00M
est: 27.48M (+493.1%)
|
256.00M
est: 185.59M (+37.9%)
|
265.00M
est: 262.22M (+1.1%)
|
181.00M
est: 262.83M (-31.1%)
|
245.00M
est: 185.90M (+31.8%)
|
253.00M
est: 242.24M (+4.4%)
|
236.00M
est: 249.27M (-5.3%)
|
190.00M
est: 127.00M (+49.6%)
|
188.00M
est: 179.00M (+5.0%)
|
143.00M
est: 212.48M (-32.7%)
|
193.59M
172.03M – 215.16M
-8.9% YoY
|
177.38M
172.53M – 182.23M
-8.4% YoY
|
221.07M
178.24M – 263.90M
+24.6% YoY
|
195.94M
180.40M – 279.42M
-11.4% YoY
|
262.24M
254.87M – 270.58M
+33.8% YoY
|
| SGA |
—
est: 212.32M (-100.0%)
|
—
est: 307.59M (-100.0%)
|
427.00M
est: 142.37M (+199.9%)
|
442.00M
est: 149.57M (+195.5%)
|
123.00M
est: 100.03M (+23.0%)
|
480.00M
est: 221.69M (+116.5%)
|
219.00M
est: 325.63M (-32.7%)
|
226.00M
est: 373.87M (-39.6%)
|
222.00M
est: 368.96M (-39.8%)
|
196.00M
est: 382.07M (-48.7%)
|
104.00M
est: 353.96M (-70.6%)
|
132.00M
est: 364.25M (-63.8%)
|
—
est: 372.95M (-100.0%)
|
265.00M
est: 374.34M (-29.2%)
|
—
est: 91.97M (-100.0%)
|
103.36M
100.68M – 105.01M
+12.4% YoY
|
104.15M
103.44M – 104.77M
+0.8% YoY
|
107.56M
103.70M – 112.12M
+3.3% YoY
|
110.99M
110.17M – 111.80M
+3.2% YoY
|
116.32M
113.81M – 119.17M
+4.8% YoY
|
| EPS |
1.62
est: 0.44 (+270.8%)
|
3.00
est: 0.56 (+433.2%)
|
2.73
est: 0.56 (+385.2%)
|
2.71
est: 0.56 (+388.1%)
|
0.01
est: 0.37 (-97.3%)
|
0.30
est: 0.34 (-11.4%)
|
0.64
est: 0.48 (+34.0%)
|
0.67
est: 0.49 (+36.4%)
|
0.46
est: 0.51 (-10.0%)
|
0.62
est: 0.55 (+12.9%)
|
0.64
est: 0.61 (+4.8%)
|
0.59
est: 0.47 (+26.1%)
|
0.47
est: 0.48 (-2.1%)
|
0.44
est: 0.54 (-18.3%)
|
0.12
est: 0.49 (-75.3%)
|
0.40
0.38 – 0.48
-17.1% YoY
|
0.40
0.39 – 0.41
-2.0% YoY
|
0.44
0.40 – 0.59
+12.5% YoY
|
0.49
0.40 – 0.62
+10.6% YoY
|
0.59
0.57 – 0.61
+19.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi Global Bioenergy UCITS ETF EUR Acc CWE.PA | 2.66% | 1.87M | 0.35% |
| 2 | Amundi Global Bioenergy UCITS ETF USD Acc CWEU.L | 2.66% | 1.87M | 0.35% |
| 3 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 1.15% | 4.90M | 0.05% |
| 4 | iShares UK Dividend UCITS ETF IUKD.SW | 0.78% | 13.45M | 0.40% |
| 5 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.68% | 459.7K | 0.09% |
| 6 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.68% | 259.4K | 0.15% |
| 7 | Invesco FTSE 250 UCITS ETF S250.L | 0.67% | 239.9K | 0.12% |
| 8 | iShares FTSE 250 UCITS ETF MIDD.L | 0.66% | 5.62M | 0.40% |
| 9 | iShares MSCI UK Small Cap UCITS ETF CUKS.L | 0.61% | 780.9K | 0.58% |
| 10 | iShares MSCI United Kingdom Small-Cap ETF EWUS | 0.61% | 245.7K | 0.59% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anthony Nicholas Seymour Hampton | Chief Executive Officer & Executive Director | 1M | male |
| Sarah Mary Kuijlaars | Chief Financial Officer & Director | 690.7K | female |
| Didier Viala | President of Americas | — | male |
| Jan-Jaap Van Der Bij | Senior Vice President of Global Environment, Health, Safety, Quality & Security | — | — |
| Kavita Karnik | Global Head of Nutrition, Regulatory & Scientific Affairs | — | — |
| Lauren Higgins | Head of Ethics and Compliance | — | female |
| Lindsay Beardsell | General Counsel | — | female |
| Melissa | Chief Commercial & Transformation Officer | — | female |
| Rowan Adams | Chief Corporate Affairs & Sustainability Officer | — | male |
| Tamsin Vine | Chief People Officer | — | female |
| Victoria Spadaro Grant | Chief Science & Innovation Officer | — | female |
| Christopher Marsh | Vice President of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TATE.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
